DGIdb - CAMPTOTHECIN Drug Record

CAMPTOTHECIN chembl:CHEMBL65 Antineoplastic

Alternate Names:

NSC-94600
CPT
(+)-CAMPTOTHECINE
(S)-CAMPTOTHECIN
20(S)-CAMPTOTHECIN
(+)-CAMPTOTHECIN
20(S)-CAMPTOTHECINE
21,22-SECOCAMPTOTHECIN-21-OIC ACID LACTONE
CAMPTOTHECIN
CAMPTOTHECINE
D-CAMPTOTHECIN
(S)-(+)-CAMPTOTHECIN
drugbank:04690
chemidplus:7689-03-4
chembl:CHEMBL65
pubchem.compound:24360

Drug Info:

FDA Approval	approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent
Drug Categories	topoisomerase i inhibitors
Drug Categories	p-glycoprotein substrates

(4 More Sources)

Publications:

Costa-Pereira et al., 2000, Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis., Br. J. Cancer
Shih et al., 2005, Ku86 modulates DNA topoisomerase I-mediated radiosensitization, but not cytotoxicity, in mammalian cells., Cancer Res.
Dong G et al., 2010, Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents., J Med Chem
Kamal A et al., 2013, 4β-[4'-(1-(Aryl)ureido)benzamide]podophyllotoxins as DNA topoisomerase I and IIα inhibitors and apoptosis inducing agents., Bioorg Med Chem
Shchekotikhin AE et al., 2014, Synthesis and evaluation of new antitumor 3-aminomethyl-4,11-dihydroxynaphtho[2,3-f]indole-5,10-diones., Eur J Med Chem
Song Y et al., 2010, Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors., J Med Chem
Wu WB et al., 2011, Synthesis and evaluation of mansonone F derivatives as topoisomerase inhibitors., Eur J Med Chem
Khadka DB et al., 2011, 3-Arylisoquinolines as novel topoisomerase I inhibitors., Bioorg Med Chem
D'yakonov VA et al., 2015, Stereoselective synthesis of 11-phenylundeca-5Z,9Z-dienoic acid and investigation of its human topoisomerase I and IIα inhibitory activity., Bioorg Med Chem Lett
Chen TC et al., 2015, Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents., Eur J Med Chem
Lemster T et al., 2009, Photochemical electrocyclisation of 3-vinylindoles to pyrido[2,3-a]-, pyrido[4,3-a]- and thieno[2,3-a]-carbazoles: design, synthesis, DNA binding and antitumor cell cytotoxicity., Eur J Med Chem
Verones V et al., 2013, Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives., Eur J Med Chem
Racané L et al., 2013, New anticancer active and selective phenylene-bisbenzothiazoles: synthesis, antiproliferative evaluation and DNA binding., Eur J Med Chem
Wang MJ et al., 2014, Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents., J Med Chem
Parrino B et al., 2014, 11H-Pyrido[3',2':4,5]pyrrolo[3,2-c]cinnoline and pyrido[3',2':4,5]pyrrolo[1,2-c][1,2,3]benzotriazine: two new ring systems with antitumor activity., J Med Chem
Fan Y et al., 1998, Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin., J Med Chem
Oppegard LM et al., 2012, Inhibition of human topoisomerases I and II by simocyclinone D8., J Nat Prod
Luo Y et al., 2012, Synthesis and biological evaluation of new homocamptothecin analogs., Eur J Med Chem
Kiselev E et al., 2014, Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells., J Med Chem
Cinelli MA et al., 2010, The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode., Bioorg Med Chem
Shchekotikhin AE et al., 2007, Naphthoindole-based analogues of tryptophan and tryptamine: synthesis and cytotoxic properties., Bioorg Med Chem
Bar FM et al., 2009, Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors., J Nat Prod
Christodoulou MS et al., 2013, Quinazolinecarboline alkaloid evodiamine as scaffold for targeting topoisomerase I and sirtuins., Bioorg Med Chem
Christodoulou MS et al., 2015, Boehmeriasin A as new lead compound for the inhibition of topoisomerases and SIRT2., Eur J Med Chem
You QD et al., 2009, Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification., J Med Chem
Nagarajan M et al., 2004, Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings., J Med Chem
Evdokimov NM et al., 2011, Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents., J Med Chem
Kiselev E et al., 2012, Azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents: a systematic study of structure-activity relationships., J Med Chem
Negi A et al., 2015, Imine/amide-imidazole conjugates derived from 5-amino-4-cyano-N1-substituted benzyl imidazole: Microwave-assisted synthesis and anticancer activity via selective topoisomerase-II-α inhibition., Bioorg Med Chem
Van HT et al., 2007, Convenient synthesis of indeno[1,2-c]isoquinolines as constrained forms of 3-arylisoquinolines and docking study of a topoisomerase I inhibitor into DNA-topoisomerase I complex., Bioorg Med Chem Lett
He S et al., 2015, Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors., ACS Med Chem Lett
Cinelli MA et al., 2009, Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships., Bioorg Med Chem
Majumdar P et al., 2015, Design, synthesis and evaluation of thiohydantoin derivatives as potent topoisomerase I (Top1) inhibitors with anticancer activity., Eur J Med Chem
Lee CC et al., 2013, Design, synthesis and antiproliferative evaluation of fluorenone analogs with DNA topoisomerase I inhibitory properties., Bioorg Med Chem
Santos RC et al., 2010, Synthesis and structure-activity relationship study of novel cytotoxic carbamate and N-acylheterocyclic bearing derivatives of betulin and betulinic acid., Bioorg Med Chem
Hecht SM et al., 1992, A strategy for identifying novel, mechanistically unique inhibitors of topoisomerase I., J Nat Prod
Zhou BN et al., 2000, Use of COMPARE analysis to discover new natural product drugs: isolation of camptothecin and 9-methoxycamptothecin from a new source., J Nat Prod
Dong G et al., 2012, New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations., J Med Chem
Kashyap M et al., 2013, Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents., Bioorg Med Chem Lett
Masurier N et al., 2012, Imidazonaphthyridine systems (part 2): Functionalization of the phenyl ring linked to the pyridine pharmacophore and its replacement by a pyridinone ring produces intriguing differences in cytocidal activity., Eur J Med Chem
Wang L et al., 2014, Suzuki coupling based synthesis and in vitro cytotoxic evaluation of 7-heteroaryl-substituted camptothecin analogs., Bioorg Med Chem Lett
Beck DE et al., 2015, Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore., J Med Chem
Taliani S et al., 2013, Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) inhibitors., J Med Chem
Di Salvo A et al., 2013, Synthesis, cytotoxicity and DNA binding of oxoazabenzo[de]anthracenes derivatives in colon cancer Caco-2 cells., Eur J Med Chem
Kiselev E et al., 2011, 7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents., J Med Chem
Chen CL et al., 2014, Ring fusion strategy for the synthesis of anthra[2,3-d]oxazole-2-thione-5,10-dione homologues as DNA topoisomerase inhibitors and as antitumor agents., Eur J Med Chem
Sović I et al., 2014, Novel phenyl and pyridyl substituted derivatives of isoindolines: Synthesis, antitumor activity and DNA binding features., Eur J Med Chem
Baviskar AT et al., 2013, Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity., Bioorg Med Chem
Teicher, 2008, Next generation topoisomerase I inhibitors: Rationale and biomarker strategies., Biochem. Pharmacol.
Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
van der Merwe et al., 2008, Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin., J. Biol. Chem.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Manita D et al., 2011, Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction., Bioorg Med Chem
Goldwasser et al., 1996, Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines., Oncol. Res.
Rajule R et al., 2012, Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study., Bioorg Med Chem
Muscarella et al., 2003, Cross-linking of surface IgM in the Burkitt's lymphoma cell line ST486 provides protection against arsenite- and stress-induced apoptosis that is mediated by ERK and phosphoinositide 3-kinase signaling pathways., J. Biol. Chem.
Chu et al., 1999, Active efflux of CPT-11 and its metabolites in human KB-derived cell lines., J. Pharmacol. Exp. Ther.
Ahmed et al., 2013, Epigenetic and genetic features of 24 colon cancer cell lines., Oncogenesis
Song et al., 2015, Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer., Clin. Cancer Res.
Wang et al., 2004, Involvement of Hus1 in the chain elongation step of DNA replication after exposure to camptothecin or ionizing radiation., Nucleic Acids Res.
Nair et al., Differential effect of camptothecin treatment on topoisomerase II alpha expression in ML-1 and HL-60 leukemia cell lines., Anticancer Res.
Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther.
Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science
Yasui et al., 2004, Alteration in copy numbers of genes as a mechanism for acquired drug resistance., Cancer Res.
Hong et al., 2004, Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model., World J. Gastroenterol.
Yamaguchi et al., 2005, Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death., Oncol. Rep.
Weller et al., 1997, Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone., Int. J. Cancer
Otsuki et al., 2007, WRN counteracts the NHEJ pathway upon camptothecin exposure., Biochem. Biophys. Res. Commun.
Lin et al., 1998, Camptothecin induces differentiation, tissue transglutaminase and apoptosis in cultured keratinocytes., Exp. Dermatol.
Park et al., 2000, Involvement of retinoblastoma family members and E2F/DP complexes in the death of neurons evoked by DNA damage., J. Neurosci.
Hetman et al., 1999, Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase., J. Biol. Chem.
Ishii et al., 2004, GSTP1 affects chemoresistance against camptothecin in human lung adenocarcinoma cells., Cancer Lett.
Jakob et al., 1994, Topoisomerase I-inhibition enhances vitamin D-responsive expression of the receptor for lipopolysaccharide binding protein CD 14., Biochem. Biophys. Res. Commun.
Kuo et al., 2006, DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors., J. Pharmacol. Exp. Ther.
Rath et al., 2006, The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells., Biochim. Biophys. Acta

CAMPTOTHECIN HUS1

Interaction Score: 3.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14762204

Sources:
NCI
CAMPTOTHECIN HNRNPA1

Interaction Score: 3.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22071521

Sources:
DTC
CAMPTOTHECIN TOP1

Interaction Score: 0.85

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name XMT-1001

Novel drug target Established target

PMIDs:
20942490 23849207 25244612 20155916 21600681 21095131 25913198 25799376 19386396 23202849 23603616 25003995 25317694 9632354 22867097 22647222 24502276 20630766 17276690 19691293 24103429 25626146 19715319 15509164 21388138 22329436 26216018 17827007 25815139 19783447 26312433 24094433 20494586 1324981 11000035 22867019 23321564 22503207 24529870 25909279 23987476 24099994 21823606 25240093 25282261 23920485 18061144 10592235 18056711 11752352

Sources:
DTC DrugBank TdgClinicalTrial ClearityFoundationClinicalTrial TTD
CAMPTOTHECIN XRCC5

Interaction Score: 0.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16230379

Sources:
NCI
CAMPTOTHECIN STAG2

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Camptothecin + Olaparib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
24356817 21852505

Sources:
JAX-CKB
CAMPTOTHECIN THBS1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16962673

Sources:
NCI
CAMPTOTHECIN COL18A1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15069724

Sources:
NCI
CAMPTOTHECIN DCK

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14973057

Sources:
NCI
CAMPTOTHECIN TGM2

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9758415

Sources:
NCI
CAMPTOTHECIN MCL1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8938795 22386982

Sources:
DTC NCI
CAMPTOTHECIN MGMT

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16258022

Sources:
NCI
CAMPTOTHECIN CDK4

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10777774

Sources:
NCI
CAMPTOTHECIN MAPK9

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10839298

Sources:
NCI
CAMPTOTHECIN BIRC5

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16211302

Sources:
NCI
CAMPTOTHECIN BAX

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9398050

Sources:
NCI
CAMPTOTHECIN GSTP1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15500952

Sources:
NCI
CAMPTOTHECIN PIK3CA

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gedatolisib + Camptothecin

Indication/Tumor Type colon cancer

Response Type sensitive

PMIDs:
12464623 24042735 25688157

Sources:
JAX-CKB NCI
CAMPTOTHECIN PIK3CB

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12464623

Sources:
NCI
CAMPTOTHECIN BDNF

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10428835

Sources:
NCI
CAMPTOTHECIN HBB

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CAMPTOTHECIN WRN

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17303082

Sources:
NCI
CAMPTOTHECIN KRAS

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gedatolisib + Camptothecin

Indication/Tumor Type colon cancer

Response Type sensitive

PMIDs:
24042735 25688157

Sources:
JAX-CKB
CAMPTOTHECIN TOP2A

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11205246

Sources:
NCI
CAMPTOTHECIN THPO

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CAMPTOTHECIN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9918583

Sources:
NCI
CAMPTOTHECIN MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CAMPTOTHECIN HIF1A

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CAMPTOTHECIN VDR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7510956

Sources:
NCI
CAMPTOTHECIN ATXN2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CAMPTOTHECIN ATAD5

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CAMPTOTHECIN HSD17B10

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CAMPTOTHECIN CYP2C19

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CAMPTOTHECIN CYP1A2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CAMPTOTHECIN NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CAMPTOTHECIN EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CAMPTOTHECIN CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB04690

Version: 5.1.7

Alternate Names:

7689-03-4 CAS Number

CHEMBL65 ChEMBL ID

Drug Info:

Drug Type small molecule

Drug Groups experimental

Drug Categories alkaloids

Publications:

van der Merwe et al., 2008, Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin., J. Biol. Chem.

Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

TdgClinicalTrial: CAMPTOTHECIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval approved

Publications:

DTC: CAMPTOTHECIN

Version: 02-September-2020

Alternate Names:

CHEMBL65 ChEMBL Drug ID

Drug Info:

Publications:

Baviskar AT et al., 2013, Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity., Bioorg Med Chem

Sović I et al., 2014, Novel phenyl and pyridyl substituted derivatives of isoindolines: Synthesis, antitumor activity and DNA binding features., Eur J Med Chem

Chen CL et al., 2014, Ring fusion strategy for the synthesis of anthra[2,3-d]oxazole-2-thione-5,10-dione homologues as DNA topoisomerase inhibitors and as antitumor agents., Eur J Med Chem

NCI: CAMPTOTHECIN

Version: 14-September-2017

Alternate Names:

C338 NCI drug code

Drug Info:

Publications:

Costa-Pereira et al., 2000, Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis., Br. J. Cancer

Shih et al., 2005, Ku86 modulates DNA topoisomerase I-mediated radiosensitization, but not cytotoxicity, in mammalian cells., Cancer Res.

Goldwasser et al., 1996, Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines., Oncol. Res.

JAX-CKB: Camptothecin

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Song et al., 2015, Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer., Clin. Cancer Res.

Ahmed et al., 2013, Epigenetic and genetic features of 24 colon cancer cell lines., Oncogenesis

Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science

TTD: Camptothecin
- Version: 2020.06.01
Alternate Names:

D09YDM TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL65
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: CAMPTOTHECIN
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

combination therapy	Camptothecin + Olaparib
Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive

combination therapy	Gedatolisib + Camptothecin
Indication/Tumor Type	colon cancer
Response Type	sensitive

Drug Type	small molecule
Drug Groups	experimental
Drug Categories	alkaloids

Trial Name	XMT-1001
Novel drug target	Established target

CAMPTOTHECIN Drug Record

CAMPTOTHECIN chembl:CHEMBL65 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14762204

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22071521

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Trial Name XMT-1001 Novel drug target Established target

Sources: DTC DrugBank TdgClinicalTrial ClearityFoundationClinicalTrial TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16230379

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Camptothecin + Olaparib Indication/Tumor Type glioblastoma multiforme Response Type sensitive

PMIDs: 24356817 21852505

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16962673

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15069724

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14973057

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9758415

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8938795 22386982

Sources: DTC NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16258022

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10777774

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10839298

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16211302

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9398050

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15500952

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Gedatolisib + Camptothecin Indication/Tumor Type colon cancer Response Type sensitive

PMIDs: 12464623 24042735 25688157

Sources: JAX-CKB NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12464623

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10428835

Sources: NCI

Interaction Types & Directionality:

n/a

PMIDs:
14762204

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22071521

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name XMT-1001

Novel drug target Established target

Sources:
DTC DrugBank TdgClinicalTrial ClearityFoundationClinicalTrial TTD

Interaction Types & Directionality:

n/a

PMIDs:
16230379

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Camptothecin + Olaparib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
24356817 21852505

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
16962673

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15069724

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14973057

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9758415

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8938795 22386982

Sources:
DTC NCI

Interaction Types & Directionality:

n/a

PMIDs:
16258022

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10777774

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10839298

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16211302

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9398050

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15500952

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gedatolisib + Camptothecin

Indication/Tumor Type colon cancer

Response Type sensitive

PMIDs:
12464623 24042735 25688157

Sources:
JAX-CKB NCI

Interaction Types & Directionality:

n/a

PMIDs:
12464623

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10428835

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
17303082

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gedatolisib + Camptothecin

Indication/Tumor Type colon cancer

Response Type sensitive

PMIDs:
24042735 25688157

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
11205246

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
9918583

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found